Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis.

Subcutaneous recombinant interferon-beta-1a (Rebif) 22 or 44 microg three times weekly is a valuable option in the first-line treatment in patients with relapsing-remitting multiple sclerosis (RRMS). It has shown benefits on outcome measures related to relapses, progression of disability and magnetic resonance imaging (MRI) in clinical trials. A significant efficacy advantage for subcutaneous interferon-beta-1a three times weekly over intramuscular interferon-beta-1a 30 microg once weekly was shown at 24 and 48 weeks. The most common adverse events are generally mild and clinically manageable. Considering both direct and indirect comparative clinical trial data, an assessment suggests that subcutaneous interferon-beta-1a 44 microg three times weekly has the best benefit-to-risk values of the available disease-modifying drugs used to treat RRMS.
AuthorsDavid Murdoch, Katherine A Lyseng-Williamson
JournalDrugs (Drugs) Vol. 65 Issue 9 Pg. 1295-312 ( 2005) ISSN: 0012-6667 [Print] New Zealand
PMID15916455 (Publication Type: Journal Article, Review)
Chemical References
  • Adjuvants, Immunologic
  • Interferon-beta
  • Interferon beta-1a
  • Adjuvants, Immunologic (adverse effects, economics, therapeutic use)
  • Clinical Trials as Topic
  • Cost-Benefit Analysis
  • Humans
  • Interferon beta-1a
  • Interferon-beta (adverse effects, economics, therapeutic use)
  • Multiple Sclerosis, Relapsing-Remitting (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: